HPTN 083

HPTN 083 is a 2016 clinical trial which compares cabotegravir injections with oral use of Emtricitabine/tenofovir as pre-exposure prophylaxis for prevention of HIV/AIDS.
The study seeks to test injectable PrEP as a way to remedy adherence for many patients on a daily pill regimen.
HPTN 083 is the first large scale Phase [III clinical trials|phase III] clinical trial of cabotegravir.
In February 2016 researchers presented the results of the ECLAIR study. That study examined cabotegravir and found no serious safety concerns.
The research is a collaboration of Gilead Sciences, HIV Prevention [Trials Network], ViiV Healthcare, National Institute of Allergy and [Infectious Diseases].
Local study sites will include John H. Stroger [Jr. Hospital of Cook County].
On May 18, 2020, HPTN announced that the long-acting injections had been found to be a highly effective treatment.